<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04839367</url>
  </required_header>
  <id_info>
    <org_study_id>CLP03</org_study_id>
    <nct_id>NCT04839367</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)</brief_title>
  <acronym>PROPELLER</acronym>
  <official_title>Positron Emission Tomography Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA: A Multi-Centre, Blinded Review, Dose Ranging Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clarity Pharmaceuticals Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clarity Pharmaceuticals Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the safety and tolerability of 64Cu-SARbisPSMA in&#xD;
      participants with untreated, confirmed Prostate Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-centre, blinded review, dose ranging, non-randomized study of&#xD;
      64Cu-SAR-bisPSMA administered to participants with confirmed Prostate Cancer. 30 eligible&#xD;
      participants will be allocated (1:1:3) to 1 of 3 dosing cohorts to be administered with&#xD;
      64Cu-SAR-bisPSMA 100 MBq, 150 MBq or 200 MBq. PET/CT scan images will be sent to blinded&#xD;
      central readers to assess the capacity of 64Cu-SAR-bisPSMA to detect primary Prostate Cancer,&#xD;
      and to detect secondary Prostate Cancer in comparison to the Reference Standard, to assess&#xD;
      image quality of the various dose cohorts, and to assess the PET/CT scan features of&#xD;
      64Cu-SAR-bisPSMA in comparison standard of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of 64Cu-SAR-bisPSMA using Common Terminology Criteria for Adverse Events version 5</measure>
    <time_frame>11 weeks</time_frame>
    <description>Safety will be assessed via vital signs, pathology tests (hematology, biochemistry, urinalysis, coagulation), physical examinations, ECGs and spontaneous AE reporting.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of 64Cu-SAR-bisPSMA in the Detection of Primary Prostate Caner Compared to Histopathology</measure>
    <time_frame>11 weeks</time_frame>
    <description>Efficacy will be measured by the proportion of 64Cu-SAR-bisPSMA PET/CT scans assessed as True Positive or False Negative for primary Prostate Cancer, as confirmed by histopathology.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of 200 MBq 64Cu-SARbisPSMA compared to the Reference Standard (which consist of histology, pathology/biochemical markers, and conventional anatomical and/or functional imaging modalities) in detecting secondary Prostate Cancer.</measure>
    <time_frame>11 weeks</time_frame>
    <description>Calculating the Positive Percentage (%) agreement and Negative Percentage (%) agreement in secondary Prostate Cancer disease status between 64Cu-SAR-bisPSMA PET/CT scans and a composite of Reference Standard modalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of image quality at varying dose levels of 64CuSAR-bisPSMA for each dose cohort (100 MBq, 150 MBq and 200 MBq).</measure>
    <time_frame>11 weeks</time_frame>
    <description>Image quality will be assessed by 2 blinded central readers.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - 100 MBq 64Cu-SAR-bisPSMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single administration, a bolus injection of 100 MBq 64Cu-SAR-bisPSMA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - 150 MBq 64Cu-SAR-bisPSMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single administration, a bolus injection of 150 MBq 64Cu-SAR-bisPSMA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - 200 MBq 64Cu-SAR-bisPSMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single administration, a bolus injection of 200 MBq 64Cu-SAR-bisPSMA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>64Cu-SAR-bisPSMA</intervention_name>
    <description>64Cu-SAR-bisPSMA</description>
    <arm_group_label>Cohort 1 - 100 MBq 64Cu-SAR-bisPSMA</arm_group_label>
    <arm_group_label>Cohort 2 - 150 MBq 64Cu-SAR-bisPSMA</arm_group_label>
    <arm_group_label>Cohort 3 - 200 MBq 64Cu-SAR-bisPSMA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent;&#xD;
&#xD;
          -  ≥18 years of age;&#xD;
&#xD;
          -  Life expectancy &gt;3 months;&#xD;
&#xD;
          -  Confirmation of Prostate Cancer by histopathology and planned radical prostatectomy;&#xD;
&#xD;
          -  Have ≥1 of the following intermediate- to high-risk features:&#xD;
&#xD;
               1. PSA level greater than or equal to 10.0 ng/ml within 12 weeks prior to enrolment;&#xD;
&#xD;
               2. International Society of Urological Pathology (ISUP) Grade Group 3 (i.e. Gleason&#xD;
                  score of 7 (4+3) or above;&#xD;
&#xD;
               3. Clinical stage greater than or equal to T2b;&#xD;
&#xD;
          -  Participants must have adequate renal function;&#xD;
&#xD;
          -  Sexually active participants who have female partners of childbearing potential:&#xD;
             Partner and/or participant must agree to use an acceptable form of contraception.&#xD;
             Further participants must refrain from donating sperm;&#xD;
&#xD;
          -  A 68Ga-PSMA-11 PET/CT scan performed within 4 weeks, but not closer than 6 hours prior&#xD;
             to the administration of 64Cu-SAR-bisPSMA.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior prostatectomy or any other treatment for Prostate Cancer, including Androgen&#xD;
             Deprivation Therapy and radiation therapy;&#xD;
&#xD;
          -  Previous treatment with PSMA-targeted therapy within 3 months prior to enrolment, and&#xD;
             administration of other investigational agents within 4 weeks prior to entering the&#xD;
             study (except 68Ga-PSMA-11);&#xD;
&#xD;
          -  Known hypersensitivity to the components of 64Cu-SAR-bisPSMA;&#xD;
&#xD;
          -  Diagnosed with other malignancies that are expected to alter life expectancy or may&#xD;
             interfere with disease assessment. However, participants with a prior history of&#xD;
             malignancy that has been adequately treated and who have been disease free for more&#xD;
             than 3 years are eligible, as are participants with adequately treated non-melanoma&#xD;
             skin cancer, superficial bladder cancer;&#xD;
&#xD;
          -  Any serious medical condition which the Investigator feels may interfere with the&#xD;
             procedures or evaluations of the study;&#xD;
&#xD;
          -  Patients unwilling or unable to comply with protocol or with a history of&#xD;
             noncompliance or inability to grant informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clarity Pharmaceuticals</last_name>
    <phone>+61 (0) 2 9209 4037</phone>
    <email>clinicaltrials@claritypharmaceuticals.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2751</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Veronica Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Louise Emmett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GenesisCare CTA, SJOG Medical Clinic</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nat Lenzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

